Biophytis: in discussions for an agreement in China

(CercleFinance.com) - Biophytis announces that it has entered into exclusive negotiations with a leading Chinese pharmaceutical company, which 'stands out for its expertise in developing innovative technologies, and its ability to access a fast-growing market'.


These discussions are aimed at finalizing a licensing agreement to co-develop and market BIO101 (20 Hydroxyecdysone) in China, in the most promising and advanced indications: viral respiratory infections, sarcopenia and obesity.

China is now the world's second-largest pharmaceutical market, with a value of $190 billion", points out Chief Business Officer Edouard Bieth, noting that obesity accounts for 70 million patients and sarcopenia for almost 30 million.

Copyright (c) 2025 CercleFinance.com. All rights reserved.